Do you have NASH/MASH and would like to take part in a clinical trial to see if an investigational drug can help reduce the inflammation and scarring (fibrosis) in your liver? Then you may be able to participate in our upcoming Phase III Clinical trial. Inquire today!

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with Compensated Cirrhosis due to NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

The purpose of this study is to find out whether the addition of HDV to Humalog® will improve diabetes control by reducing high blood sugar after meals and/or reducing the risk of low blood sugar (hypoglycemia) during insulin treatment. The safety and tolerability of Humalog® with or without added HDV will also be evaluated. The study drugs will be administered by subcutaneous (under the skin) injection.

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

We are seeking participants with type 2 diabetes who use insulin and whose diabetes has affected kidney function and are interested in trying out a new medication that is expected to improve blood sugar control and prevent the weight gain (or induce weight loss) associated with increased insulin use. Compensation for time and travel are provided.

The purpose of this study is to compare diet (record of the foods you eat), gut microbiome (stool sample), and cells (blood sample) in adults with IgA Nephropathy (IgAN) and compare with adults with focal segmental glomerulosclerosis (FSGS) and adults with no history of medical problems. The information we learn by doing this study may help us understand how we might be able to target the microbiome to better understand the disease process and potentially help us develop new therapies in the future.

This is a study for people with chronic kidney disease and type 1 diabetes. In this study, we want to learn more about the effectiveness and safety of a kidney drug called finerenone compared to a placebo.

The study treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this study, the researchers want to learn if finerenone works the same way in kidney transplant recipients. Some subjects will receive the study drug and some will receive a placebo.

Have you ever wondered what environmental toxins you are exposed to on a daily basis, and how it might affect your health? The STRIVE study is looking for volunteers who would like to provide blood, urine, and/or saliva, as well as home samples such as soil, dust, and/or water. In this study, we want to learn more about the environmental factors that contribute to advanced liver disease and liver cancer. We are looking for healthy volunteers and people with liver cirrhosis who live in either North Carolina or Georgia to take part.